256抗甲状腺药物肝损伤临床诊治进展

doi:10.3969/j.issn.1672-5069.2017.02.003

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (2): 135-138.doi: 10.3969/j.issn.1672-5069.2017.02.003

256抗甲状腺药物肝损伤临床诊治进展

王玉霞，都健

110032 沈阳市中国医科大学附属第四医院内分泌科

收稿日期:2017-01-02 出版日期:2017-04-10 发布日期:2017-06-07
通讯作者: 都健，E-mail：dujianbox@126.com
作者简介:王玉霞，女，医学博士，主任医师。E-mail:cmu4h_wyx@126.com

Diagnostic and therapeutic progress in anti-thyroid drug -induced liver injury

Wang Yuxia，Du Jian.

Department of Endocrinology，Forth Affiliated Hospital，China Medical University，Shenyang 110032，China

Received:2017-01-02 Online:2017-04-10 Published:2017-06-07

摘要/Abstract

关键词: 药物性肝损伤, 抗甲状腺药物, 进展

Key words: Drug-induced liver injury, Anti-thyroid drugs, Progress

王玉霞，都健. 256抗甲状腺药物肝损伤临床诊治进展[J]. 实用肝脏病杂志, 2017, 20(2): 135-138.

Wang Yuxia，Du Jian.. Diagnostic and therapeutic progress in anti-thyroid drug -induced liver injury[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 135-138.

[1] David S，Cooper MD. Antithyroid drugs. N Engl J Med，1984，311（21）:1353-1362.
[2] Bhuyan AK，Sarma D，Kaimal Saikia U，et al. Grave's disease with severe hepatic dysfunction:A diagnostic and therapeutic challenge. Case Rep Med，2014，2014:790458.
[3] Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract，2002，8（3）:222-224.
[4] Mathew J，Sundrarajan RS，Gomadam S. Anti-thyroid drugs in pediatric Graves' disease. Indian J Endocrinol Metab，2015，19（3）:340-346.
[5] Shen C，Zhao CY，Liu F，et al. Acute-on-chronic liver failure due to thiamazole in a patient with hyperthyroidism and trilogy of Fallot:case report. BMC Gastroenterol，2010，10:93.
[6] Jeon SJ，Kim TY，Lee SH，et al. A case report of methimazole-induced acute liver failure successfully treated with liver transplantation. Kor J Med，2012，83（3）:363-368.
[7] Jie EL，Ye AK，Kim LK，et al. A case of acute liver failure associated with methimazole in patient with underlying liver disease. Soonchunhyang Med Sci，2014，20（2）:195-200.
[8] Zou H，Jin L，Wang LR，et al. Methimazole-induced cholestatic hepatitis:two cases report and literature review. Oncotarget，2016，7（4）:5088-5091.
[9] Wang MT，Lee WJ，Huang TY，et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients:a population-based cohort study. Br J Clin Pharmacol，2014，78（3）:619-629.
[10] Yang J，Li LF，Xu Q，et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid，2015，25（3）:278-283.
[11] Rivkees SA，Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med，2009，360（15）:1574-1575.
[12] Malozowski S，Chiesa A. Propylthiouracil-induced hepatotoxicity and death. Hopefully，never more. J Clin Endocrinol Metab，2010，95（7）:3161-3163.
[13] Yang J，Zhang J，Xu Q，et al. Unusual synchronous methimazole-induced agranulocytosis and severe hepatotoxicity in patient with hyperthyroidism:A case report and review of the literature. Int J Endocrinol，2015，2015:934726.
[14] Heidari R，Niknahad H，Jamshidzadeh A.et al. Factors affecting drug-induced liver injury:antithyroid drugs as instances. Clin Mol Hepatol，2014，20（3）:237-248.
[15] Zhu H，Zhang Z，Wang H，et al. The efficacy and safety of lithium carbonate in combination with radioactive iodine therapy of hyperthyroidism:A meta-analysis and systematic review. Int J Clin Exp Med，2016，9（7）:12721-12728.
[16] Kobayashi M，Higuchi S，Ide M，et al. Th2 cytokine-mediated methimazole-induced acute liver injury in mice. J Appl Toxicol，2012，32（10）:823-833.
[17] Cooper DS.Antithyroid drugs. N Engl J Med，2005，352（9）:905-917.
[18] Mizutani T，Yoshida K，Murakami M，et al. Evidence for the involvement of N-methylthiourea，a ring cleavage metabolite，in the hepatotoxicity of methimazole in glutathione-depleted mice:structure-toxicity and metabolic studies. Chem Res Toxicol，2000，13（3）:170-176.
[19] Heidari R，Babaei H，Eghbal M. Mechanisms of methimazole cytotoxicity in isolated rat hepatocytes. Drug Chem Toxicol，2013，36（4）:403-411.
[20] Heidari R，Babaei H，Roshangar L，et al. Effects of enzyme induction and/or glutathione depletion on methimazole-induced hepatotoxicity in mice and the protective role of N-acetylcysteine. Adv Pharm Bull，2014，4（1）:21-28.
[21] Akai S，Uematsu Y，Tsuneyama K，et al. Kupffer cell-mediated exacerbation of methimazole-induced acute liver injury in rats. J Appl Toxicol，2016，36（5）:702-715.
[22] Heidari R，Niknahad H，Jamshidzadeh A，et al. Factors affecting drug-induced liver injury:antithyroid drugs as instances. Clin Mol Hepatol，2014，20（3）:237-248.
[23] Karras S，Memi E，Kintiraki E，et al. Pathogenesis of propylthiouracil-related hepatotoxicity in children:present concepts. J Pediatr Endocrinol Metab，2012，25（7-8）:623-630.
[24] Kariya K，Sawahata T，Okuno S，et al. Inhibition of hepatic glutathione transferases by propylthiouracil and its metabolites. Biochem Pharmacol，1986，35（9）:1475-147.
[25] 齐艳霞. 甲状腺功能亢进症患者服用抗甲状腺药物出现肝损害的病例分析. 中国现代药物应用，2013，7（23）:156-157.
[26] Beniehou C. Criteria of drug induced liver disorder，Report of international consensus meeting.J He Patol，1990，11（2）:272-276.
[27] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南（2015年版）. 实用肝脏病杂志，2017，20（2）:Ⅰ—ⅩⅧ.
[28] 沈芸，薛海波. 抗甲状腺药物治疗甲状腺功能亢进合并慢性乙型肝炎的疗效及安全性. 中国现代医生，2015，10（9）:83-87.
[29] Ross DS，Burch HB，Cooper DS，et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid，2016 26（10）:1343-1421.
[30] Bahn RS，Burch HB，Cooper DS，et al. Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract，2011，17（3）:456-520.

256抗甲状腺药物肝损伤临床诊治进展

Diagnostic and therapeutic progress in anti-thyroid drug -induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨东亮, 刘嘉, 吴珺, 郑昕. 肝脏免疫学研究若干进展与挑战[J]. 实用肝脏病杂志, 2019, 22(5): 609-612.
[2]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[3]	吴欣, 郭杨志, 杜霄壤, 吴孟晋, 朱云, 冯兴中. 75例中药诱导的肝损伤患者临床特征分析*[J]. 实用肝脏病杂志, 2019, 22(5): 668-671.
[4]	张婷婷（综述）, 王煊（审校）. 肝硬化患者口服葡萄糖耐量试验临床意义及研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 449-452.
[5]	孙韬华,刘振胜,辛永宁. 酒精性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 156-159.
[6]	刘立伟,赵新颜. 药物性肝损伤临床与组织病理学特点[J]. 实用肝脏病杂志, 2019, 22(2): 160-163.
[7]	黄春洋,单晶,廖慧钰,黄云丽,韩莹,张小丹,杜晓菲,任美欣,边新渠,刘燕敏. 甲基强的松龙治疗药物性肝损伤患者临床及实验室特点分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 208-211.
[8]	吴秀欣,张惠勇,张凯. 抗结核药物所致肝损伤患者血浆MiRNA-4284水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 212-215.
[9]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[10]	孙文静, 陈东风. UCAM和Maria诊断标准用于评估1352例中国人药物性肝损伤文献分析[J]. 实用肝脏病杂志, 2018, 21(6): 881-884.
[11]	佟欣, 樊华. 双环醇治疗胃癌化疗所致肝损伤患者肝功能指标的变化[J]. 实用肝脏病杂志, 2018, 21(4): 625-626.
[12]	刘聪, 王婷婷, 左莉莉, 甄萍. 近3年住院患者药物性肝损伤状况调查[J]. 实用肝脏病杂志, 2018, 21(4): 639-640.
[13]	刘靓懿, 宿冬远. 药物性肝损伤与自身免疫性肝炎临床和肝组织病理学特征比较研究[J]. 实用肝脏病杂志, 2018, 21(3): 463-464.
[14]	陈杰, 范作鹏, 梁珊, 聂巍, 仇丽霞, 杨海霞, 林伟, 刘义荣, 张晶, 胡中杰. 合并慢性胆汁淤积性肝病对慢性药物性肝损害患者临床表现及对治疗应答的影响*[J]. 实用肝脏病杂志, 2017, 20(6): 720-723.
[15]	阮圣霆，夏光云. 异甘草酸镁与还原型谷胱甘肽治疗抗类风湿药物诱发的药物性肝损伤患者疗效比较[J]. 实用肝脏病杂志, 2017, 20(5): 608-609.